Company intelligence / Profile preview

Defensia

San Francisco, California, USA

Ownership: Private
Development stage: Other

Overview

Defensia is a biotechnology company focused on developing a new class of therapeutics for oral health, specifically targeting periodontal disease. The company utilizes a proprietary platform to design synthetic defensin-mimetic peptides that mimic the natural immune response to oral pathogens. Their lead programs aim to treat periodontitis and peri-implantitis by neutralizing key bacterial triggers and modulating the inflammatory response. Defensia was part of the Y Combinator Winter 2019 cohort and is based in San Francisco, California.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Peptides
Industry: Biotech

Beyond the preview

Go deeper on Defensia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Defensia.

Explore the full profile